Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 2/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458977 | 0.85 | PIK3CG (0.58) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL4449231 | 0.84 | NOS1 (0.60) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL4451834 | 0.79 | NOS1 (0.51) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL4454683 | 0.78 | NOS1 (0.60) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL4446550 | 0.78 | NOS1 (0.52) | NOS1PIK3CGSYKGAK | |
| SCHEMBL4411111 | 0.77 | NOS1 (0.67) | NOS1NEK2GAK | |
| SCHEMBL6063528 | 0.77 | NOS1 (0.68) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL5514530 | 0.77 | NOS1 (0.59) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL17933665 | 0.76 | NEK2 (0.44) | NOS1PIK3CGPIK3CAPIK3CBSYK | |
| SCHEMBL5523882 | 0.75 | NOS1 (0.74) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HAVCR2, TYMP, HCCS | NOS1 3411/4885PIK3CG 3147/4885PIK3CA 2945/4885 |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | NOS1 107/4885PIK3CG 1315/4885PIK3CA 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.